{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T22:48:49Z","timestamp":1777070929979,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["18K07885"],"award-info":[{"award-number":["18K07885"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["21K07804"],"award-info":[{"award-number":["21K07804"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["18K07798"],"award-info":[{"award-number":["18K07798"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","award":["15K09664"],"award-info":[{"award-number":["15K09664"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.thromres.2024.03.023","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:37:13Z","timestamp":1711154233000},"page":"37-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro"],"prefix":"10.1016","volume":"237","author":[{"given":"Koji","family":"Yada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsume","family":"Fujitate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehisa","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10 Suppl","key":"10.1016\/j.thromres.2024.03.023_bb0005","first-page":"7","article-title":"Risk factors for inhibitor development in hemophilia a","volume":"85","author":"Oldenburg","year":"2000","journal-title":"Haemotologica"},{"issue":"6","key":"10.1016\/j.thromres.2024.03.023_bb0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1055\/s-0038-1648230","article-title":"Treatment regimens with bypassing agents in patients with hemophilia a and inhibitors: a survey from the Italian Association of Hemophilia Centers (AICE)","volume":"44","author":"Coppola","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.03.023_bb0015","first-page":"124","article-title":"Recombinant factor VIIa (Novoseven\u00ae) in the treatment of internal bleeding in patients with factor VII and IX inhibitors","volume":"26","author":"Lusher","year":"1996","journal-title":"Haemostasis"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.03.023_bb0020","first-page":"19","article-title":"The treatment of factor VIII inhibitors - a general overview","volume":"70","author":"White","year":"1996","journal-title":"Vox Sang."},{"issue":"6","key":"10.1016\/j.thromres.2024.03.023_bb0025","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1538-7836.2004.00759.x","article-title":"Recombinant factor VIIa: review of efficacy, dosing regimen and safety in patients with congenital and acquired factor VIII or IX inhibitors","volume":"2","author":"Abshire","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.023_bb0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2516.2004.00924.x","article-title":"Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia a and a high responding inhibitor","volume":"10","author":"Hayashi","year":"2004","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2024.03.023_bb0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12185-014-1572-4","article-title":"Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia a patients with inhibitor","volume":"99","author":"Ogiwara","year":"2014","journal-title":"Int. J. Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.023_bb0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2516.2004.00912.x","article-title":"Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors","volume":"10","author":"Schneiderman","year":"2004","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.thromres.2024.03.023_bb0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2516.2007.01451.x","article-title":"Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience","volume":"13","author":"Schneiderman","year":"2007","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2024.03.023_bb0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2516.2007.01635.x","article-title":"Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia a, inhibitor presence and refractory bleeding","volume":"14","author":"Economou","year":"2008","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.023_bb0055","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5045\/br.2013.48.4.282","article-title":"Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience","volume":"48","author":"Han","year":"2013","journal-title":"Blood Res."},{"key":"10.1016\/j.thromres.2024.03.023_bb0060","doi-asserted-by":"crossref","unstructured":"Tomokiyo K, et al., A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone, Vox Sang. 85(4) (2003) 290\u20139. https:\/\/doi.org\/https:\/\/doi.org\/10.1111\/j.0042-9007.2003.00365.x.","DOI":"10.1111\/j.0042-9007.2003.00365.x"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.023_bb0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2516.2011.02548.x","article-title":"Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - phase I trial","volume":"18","author":"Shirahata","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2024.03.023_bb0070","doi-asserted-by":"crossref","unstructured":"Shirahata A, et al., Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report, Haemophilia. 19(2) (2013) 330\u20137. doi: https:\/\/doi.org\/10.1111\/hae.12024.","DOI":"10.1111\/hae.12024"},{"issue":"6","key":"10.1016\/j.thromres.2024.03.023_bb0075","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/hae.12205","article-title":"A phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics\/pharmacodynamics","volume":"19","author":"Shirahata","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2024.03.023_bb0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hae.13050","article-title":"A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors","volume":"23","author":"Shinkoda","year":"2017","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.thromres.2024.03.023_bb0085","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/hae.14710","article-title":"Plasma-derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors","volume":"29","author":"Sakai","year":"2023","journal-title":"Haemophilia"},{"issue":"10","key":"10.1016\/j.thromres.2024.03.023_bb0090","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia a model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.023_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PloS One"},{"issue":"21","key":"10.1016\/j.thromres.2024.03.023_bb0100","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia a","volume":"374","author":"Shima","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.thromres.2024.03.023_bb0105","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in hemophilia a patients with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.thromres.2024.03.023_bb0110","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hae.13848","article-title":"A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia a without inhibitors","volume":"25","author":"Shima","year":"2019","journal-title":"Haemophilia"},{"issue":"16","key":"10.1016\/j.thromres.2024.03.023_bb0115","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia a with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2024.03.023_bb0120","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia a (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.thromres.2024.03.023_bb0125","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia a with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"Levy","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2024.03.023_bb0130","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"Nogami","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2024.03.023_bb0135","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1021\/bi00507a028","article-title":"Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside","volume":"20","author":"Mimms","year":"1981","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.thromres.2024.03.023_bb0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/MBC.0b013e32833c9a9f","article-title":"Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII","volume":"21","author":"Ogiwara","year":"2010","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"4","key":"10.1016\/j.thromres.2024.03.023_bb0145","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.14148","article-title":"The utility of thromboelastography in inherited and acquired bleeding disorders","volume":"174","author":"Nogami","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.thromres.2024.03.023_bb0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bjh.15525","article-title":"Emicizumab-mediated haemostatic function in patients with haemophilia a is down-regulated by activated protein C through inactivation of activated factor V","volume":"183","author":"Yada","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2024.03.023_bb0155","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","article-title":"A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X","volume":"112","author":"Ogiwara","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"7","key":"10.1016\/j.thromres.2024.03.023_bb0160","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"16","key":"10.1016\/j.thromres.2024.03.023_bb0165","doi-asserted-by":"crossref","first-page":"11849","DOI":"10.1074\/jbc.M609283200","article-title":"Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium","volume":"282","author":"Ghosh","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.thromres.2024.03.023_bb0170","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/jth.14881","article-title":"Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms","volume":"18","author":"Keshava","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"15","key":"10.1016\/j.thromres.2024.03.023_bb0175","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/bloodadvances.2016004143","article-title":"Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action","volume":"1","author":"Keshava","year":"2017","journal-title":"Blood Adv."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T05:20:12Z","timestamp":1714108812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":35,"alternative-id":["S0049384824001038"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.023","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}